Eli Lilly 28. Apr. 2026 Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace
Eli Lilly 28. Apr. 2026 Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing - Fierce Biotech
Eli Lilly 28. Apr. 2026 Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine - Business Wire
Eli Lilly 27. Apr. 2026 Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs - CNBC
Eli Lilly 27. Apr. 2026 Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet - Reuters
Eli Lilly 27. Apr. 2026 Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax - Fierce Biotech